CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma

CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma

CD229 (Ly9) homophilic receptor, which belongs to the SLAM family of cell-surface molecules, is predominantly expressed on B and T cells. It acts as a signaling molecule, regulating lymphocyte homoeostasis and activation. Studies of CD229 function indicate that this receptor functions as a regulator...

Full description

Bibliographic Details
Main Authors: de Larrea, C.F (Author), Engel, P. (Author), García, J.F (Author), García-González, Á (Author), Jiménez, S. (Author), Maestre, L. (Author), Mena, M.-P (Author), Montes-Moreno, S. (Author), Piris, M.Á (Author), Puñet-Ortiz, J. (Author), Reyes-García, A.I (Author), Rodríguez-Justo, M. (Author), Rodríguez-Lobato, L.G (Author), Roncador, G. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
B cells
CD229
leukemia
Ly9
lymphoma
myeloma
soluble receptor
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items